Following recent news regarding potential ties of acetaminophen (paracetamol/Tylenol) use/overuse/misuse to Autism, we felt compelled to share our thoughts – based on the research.
The announcement lists a meta-analysis of 46 studies as the basis of new guidelines on acetaminophen use. Notably, some of the studies in this analysis found modest positive associations, while others found none. Furthermore, these studies were not consistent in either design or objective: Some studies compared maternal acetaminophen use during pregnancy between siblings. Others highlighted how acetaminophen is used to relieve discomfort which, in itself, could affect neurodevelopment. While animal studies suggested pathways to explain how acetaminophen could affect fetal brain development, these pathways have not yet been officially proven in humans.
The fact is that Autism is not a single disease, but rather an umbrella of neuro-developmental differences, a label for symptoms, but not a medical diagnosis. This fact complicates the search for “cause and effect”. The “simplest” way to view this is that there are multiple “autisms”, each with its own individual causes.
With genetics, environment, nutrition, and a myriad of other external factors as possible causes, there is no single way to identify a “cure”. Because of this complexity, many researchers think of exposures like acetaminophen not as “the cause” but as possible modifiers or risk enhancers in the presence of other vulnerabilities.
At Gray Matters, we never profess to “cure” someone’s neurodevelopmental disabilities or “autisms”. Instead, we focus on how to improve symptoms and address difficulties by treating each patient as a unique individual.
Our assessments are uniquely comprehensive, combining brain imaging, genetic testing, and nutritional analysis. This approach not only shows the unique contributions of various influences on an individual’s difficulties, but also how best to help them, one patient at a time.